Cargando…

Vertebrate TFPI-2 C-terminal peptides exert therapeutic applications against Gram-negative infections

BACKGROUND: Tissue factor pathway inhibitor-2 (TFPI-2) is a serine protease inhibitor that exerts multiple physiological and patho-physiological activities involving the modulation of coagulation, angiogenesis, tumor invasion, and apoptosis. In previous studies we reported a novel role of human TFPI...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasetty, Gopinath, Smeds, Emanuel, Holmberg, Emelie, Wrange, Louise, Adikesavan, Selvi, Papareddy, Praveen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924314/
https://www.ncbi.nlm.nih.gov/pubmed/27349742
http://dx.doi.org/10.1186/s12866-016-0750-3
_version_ 1782439849433759744
author Kasetty, Gopinath
Smeds, Emanuel
Holmberg, Emelie
Wrange, Louise
Adikesavan, Selvi
Papareddy, Praveen
author_facet Kasetty, Gopinath
Smeds, Emanuel
Holmberg, Emelie
Wrange, Louise
Adikesavan, Selvi
Papareddy, Praveen
author_sort Kasetty, Gopinath
collection PubMed
description BACKGROUND: Tissue factor pathway inhibitor-2 (TFPI-2) is a serine protease inhibitor that exerts multiple physiological and patho-physiological activities involving the modulation of coagulation, angiogenesis, tumor invasion, and apoptosis. In previous studies we reported a novel role of human TFPI-2 in innate immunity by serving as a precursor for host defense peptides. Here we employed a number of TFPI-2 derived peptides from different vertebrate species and found that their antibacterial activity is evolutionary conserved although the amino acid sequence is not well conserved. We further studied the theraputic potential of one selected TFPI-2 derived peptide (mouse) in a murine sepsis model. RESULTS: Hydrophobicity and net charge of many peptides play a important role in their host defence to invading bacterial pathogens. In vertebrates, the C-terminal portion of TFPI-2 consists of a highly conserved cluster of positively charged amino acids which may point to an antimicrobial activity. Thus a number of selected C-terminal TFPI-2 derived peptides from different species were synthesized and it was found that all of them exert antimicrobial activity against E. coli and P. aeruginosa. The peptide-mediated killing of E. coli was enhanced in human plasma, suggesting an involvement of the classical pathway of the complement. Under in vitro conditions the peptides displayed anti-coagulant activity by modulating the intrinsic pathway of coagulation and in vivo treatment with the mouse derived VKG24 peptide protects mice from an otherwise lethal LPS shock model. CONCLUSIONS: Our results suggest that the evolutionary conserved C-terminal part of TFPI-2 is an interesting agent for the development of novel antimicrobial therapies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12866-016-0750-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4924314
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49243142016-06-29 Vertebrate TFPI-2 C-terminal peptides exert therapeutic applications against Gram-negative infections Kasetty, Gopinath Smeds, Emanuel Holmberg, Emelie Wrange, Louise Adikesavan, Selvi Papareddy, Praveen BMC Microbiol Research Article BACKGROUND: Tissue factor pathway inhibitor-2 (TFPI-2) is a serine protease inhibitor that exerts multiple physiological and patho-physiological activities involving the modulation of coagulation, angiogenesis, tumor invasion, and apoptosis. In previous studies we reported a novel role of human TFPI-2 in innate immunity by serving as a precursor for host defense peptides. Here we employed a number of TFPI-2 derived peptides from different vertebrate species and found that their antibacterial activity is evolutionary conserved although the amino acid sequence is not well conserved. We further studied the theraputic potential of one selected TFPI-2 derived peptide (mouse) in a murine sepsis model. RESULTS: Hydrophobicity and net charge of many peptides play a important role in their host defence to invading bacterial pathogens. In vertebrates, the C-terminal portion of TFPI-2 consists of a highly conserved cluster of positively charged amino acids which may point to an antimicrobial activity. Thus a number of selected C-terminal TFPI-2 derived peptides from different species were synthesized and it was found that all of them exert antimicrobial activity against E. coli and P. aeruginosa. The peptide-mediated killing of E. coli was enhanced in human plasma, suggesting an involvement of the classical pathway of the complement. Under in vitro conditions the peptides displayed anti-coagulant activity by modulating the intrinsic pathway of coagulation and in vivo treatment with the mouse derived VKG24 peptide protects mice from an otherwise lethal LPS shock model. CONCLUSIONS: Our results suggest that the evolutionary conserved C-terminal part of TFPI-2 is an interesting agent for the development of novel antimicrobial therapies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12866-016-0750-3) contains supplementary material, which is available to authorized users. BioMed Central 2016-06-27 /pmc/articles/PMC4924314/ /pubmed/27349742 http://dx.doi.org/10.1186/s12866-016-0750-3 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kasetty, Gopinath
Smeds, Emanuel
Holmberg, Emelie
Wrange, Louise
Adikesavan, Selvi
Papareddy, Praveen
Vertebrate TFPI-2 C-terminal peptides exert therapeutic applications against Gram-negative infections
title Vertebrate TFPI-2 C-terminal peptides exert therapeutic applications against Gram-negative infections
title_full Vertebrate TFPI-2 C-terminal peptides exert therapeutic applications against Gram-negative infections
title_fullStr Vertebrate TFPI-2 C-terminal peptides exert therapeutic applications against Gram-negative infections
title_full_unstemmed Vertebrate TFPI-2 C-terminal peptides exert therapeutic applications against Gram-negative infections
title_short Vertebrate TFPI-2 C-terminal peptides exert therapeutic applications against Gram-negative infections
title_sort vertebrate tfpi-2 c-terminal peptides exert therapeutic applications against gram-negative infections
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924314/
https://www.ncbi.nlm.nih.gov/pubmed/27349742
http://dx.doi.org/10.1186/s12866-016-0750-3
work_keys_str_mv AT kasettygopinath vertebratetfpi2cterminalpeptidesexerttherapeuticapplicationsagainstgramnegativeinfections
AT smedsemanuel vertebratetfpi2cterminalpeptidesexerttherapeuticapplicationsagainstgramnegativeinfections
AT holmbergemelie vertebratetfpi2cterminalpeptidesexerttherapeuticapplicationsagainstgramnegativeinfections
AT wrangelouise vertebratetfpi2cterminalpeptidesexerttherapeuticapplicationsagainstgramnegativeinfections
AT adikesavanselvi vertebratetfpi2cterminalpeptidesexerttherapeuticapplicationsagainstgramnegativeinfections
AT papareddypraveen vertebratetfpi2cterminalpeptidesexerttherapeuticapplicationsagainstgramnegativeinfections